Fundz

Candel Therapeutics

Massachusetts, United States · Biopharma, Biotechnology, Health Care

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is known for its first-in-class oncolytic viral immunotherapy candidate, CAN-3110, which targets Nestin-positive tumors. They aim to extend cancer treatment options beyond traditional methods and focus on innovative therapeut

Key facts

Headquarters
Massachusetts, United States
Employees
38
Industries
Biopharma, Biotechnology, Health Care
Status
Public (CADL)
Website
candeltx.com
LinkedIn
Company page

Recent activity at Candel Therapeutics

  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01): Candel Therapeutics, Inc. filed an 8-K report to disclose information under Regulation FD on September 9, 2026. The filing includes an investor presentation (Exhibit 99.1) that the company plans to use in discussions with investors, analysts, and other parties. This presentation aims to provide insights into the company's business operations and strategic initiatives to enhance transparency with stakeholders. The presentation's content is not considered filed under the Exchange Act but is provided to meet the regulatory requirements of Regulation FD.
  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01): On May 15, 2026, Candel Therapeutics, Inc. conducted an investor presentation via live webcast to discuss extended follow-up data from their phase 3 clinical trial of aglatimagene besadenovec in localized prostate cancer. This data was also shared at the American Urological Association 2026 Annual Meeting, which took place on the same date. The company issued a press release on May 15, 2026, announcing these events, indicating a strategic effort to inform investors and stakeholders about progress in their clinical trials. The investor presentation and press release, furnished as Exhibit 99.1 and Exhibit 99.2, respectively, provide detailed insights on the company's advancements in cancer treatment.
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On February 19, 2026, Candel Therapeutics, Inc. entered into a purchase and sale agreement with RTW Investments, LP, wherein RTW will pay $100 million upon FDA marketing approval of Candel's product CAN-2409 for prostate cancer. The agreement includes tiered royalties based on net sales of the product, with specific provisions for a ratchet increasing royalty rates if sales targets are not met. There are significant conditions and a Buy-Out Option linked to change of control scenarios. The transaction is contingent on FDA approval and other customary closing conditions, which demonstrates strategic implications for Candel's future revenue structure and potential partnerships.
  • : SEC 8-K (7.01): On December 5, 2025, Candel Therapeutics, Inc. hosted a virtual Research and Development Day to showcase its viral immunotherapy approach and oncology-focused pipeline. The event highlighted key developments and strategies planned by the company. A presentation related to the R&D Day was made available as Exhibit 99.1 of the Form 8-K and also on the company's investor relations website, emphasizing the innovations in their research. This event is significant as it provides insights into the future direction of Candel Therapeutics and its impact on the oncology market.
  • : SEC 8-K (1.01): On October 14, 2025, Candel Therapeutics, Inc. entered into a Loan and Security Agreement (LSA) with Trinity Capital Inc. as the administrative agent to secure debt capital totaling up to $130.0 million. The LSA includes multiple tranches: an initial loan of $50.0 million, with additional amounts contingent on achieving specific regulatory and operational milestones. The Company incurs a commitment fee of 1.0% for drawn amounts, secured by a first priority interest in its assets. The loans are due by October 1, 2030, and the company must also pay an Exit Fee of 4.25% upon maturity or early termination. This capital infusion is aimed at supporting the Company's operational and clinical efforts, essential for its ongoing projects in therapeutics.
  • : Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
  • : Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Leadership

  • Paul B. Manning, Director
  • Edward J. Benz, Jr., M.D., Director
  • Seshu Tyagarajan, Chief Technical and Development Officer
  • Ileen Winick, Chief People Officer
  • John Christie, Scientist Ii
  • Lynda Sefton, Lead Upstream Scientist
  • Brianne Caruso, Hr Manager
  • Paul Peter Tak, President, CEO, and Board Director
  • Anne R Diers, Vice President, Research
  • Carmen Ferra, Senior Vice President Quality
  • Charles Schoch, Chief Financial Officer

Verified email and direct lines for Candel Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Candel Therapeutics in the news

Companies similar to Candel Therapeutics

About Candel Therapeutics: questions and answers

What does Candel Therapeutics do?

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is known for its first-in-class oncolytic viral immunotherapy candidate, CAN-3110, which targets Nestin-positive tumors. They aim to extend cancer treatment options beyond traditional methods and focus on innovative therapeut

Where is Candel Therapeutics headquartered?

Candel Therapeutics is headquartered in Massachusetts, United States.

How many employees does Candel Therapeutics have?

Candel Therapeutics has about 38 employees.

Who leads Candel Therapeutics?

Paul Peter Tak is a President, CEO, and Board Director at Candel Therapeutics.

What is the latest news on Candel Therapeutics?

On Sep 10, 2026, SEC 8-K (5.02):

Is Candel Therapeutics a public company?

Yes. Candel Therapeutics is publicly traded under the ticker CADL.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Candel Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.